Page 26 - Read Online

Page 351 Giliberti et al. J Transl Genet Genom 2024;8:340-54 https://dx.doi.org/10.20517/jtgg.2024.41

Financial support and sponsorship
None.

Conflicts of interest
Gesualdo L received grant support from Abionyx and Sanofi to his university department (DIMEPRE-1); he
has been a member of advisory boards for AstraZeneca, Baxter, Chinook, GSK, Mundipharma, Novartis,
Pharmadoc, Roche, Sanofi, Travere, and Vifor Pharma, and invited speaker at meetings supported by
AstraZeneca, Astellas, Estor, Takeda, Amicus, Fresenius, Werfen, Medtronic, Travere, and GSK. Giliberti M
has been a member of advisory boards for BioCryst and Kyowa Kirin and was invited speaker at meetings
supported by Sanofi, Takeda, Amicus, Kyowa Kirin, Alnylam, Chiesi, and AstraZeneca. The other authors
have declared that they have no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2024.

REFERENCES
1. Askari H, Kaneski CR, Semino-Mora C, et al. Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows
Arch 2007;451:823-34. DOI
2. Amodio F, Caiazza M, Monda E, et al. An overview of molecular mechanisms in Fabry disease. Biomolecules 2022;12:1460. DOI
PubMed PMC
3. Desnick RJ. Chapter 38 - Fabry disease: α-galactosidase a deficiency; In: Rosenberg’s molecular and genetic basis of neurological and
psychiatric disease, 5th edition; 2015. pp. 419-30. DOI
4. Schiffmann R, Hughes DA, Linthorst GE, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions
from a “Kidney disease: improving global outcomes” (KDIGO) controversies conference. Kidney Int 2017;91:284-93. DOI
5. Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N Engl J Med
2016;375:545-55. DOI
6. Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for
patients with classic Fabry disease. Mol Genet Metab 2022;137:49-61. DOI
7. Arends M, Wanner C, Hughes D, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc
Nephrol 2017;28:1631-41. DOI PubMed PMC
8. Ramaswami U, Beck M, Hughes D, et al. Cardio- renal outcomes with long- term agalsidase alfa enzyme replacement therapy: a 10-
year Fabry outcome survey (FOS) analysis. Drug Des Devel Ther 2019;13:3705-15. DOI PubMed PMC
9. Bichet DG, Torra R, Wallace E, et al. Long-term follow-up of renal function in patients treated with migalastat for Fabry disease. Mol
Genet Metab Rep 2021;28:100786. DOI
10. Johnson FK, Mudd PN Jr, Bragat A, Adera M, Boudes P. Pharmacokinetics and safety of migalastat HCl and effects on agalsidase
activity in healthy volunteers. Clin Pharmacol Drug Dev 2013;2:120-32. DOI PubMed
11. Lerario S, Monti L, Ambrosetti I, et al. Fabry disease: a rare disorder calling for personalized medicine. Int Urol Nephrol
2024;56:3161-72. DOI PubMed PMC
12. Schiffmann R, Goker-Alpan O, Holida M, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry
disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year Phase 1/2 clinical trial. J Inherit Metab
Dis 2019;42:534-44. DOI
13. Cox TM. Innovative treatments for lysosomal diseases. Best Pract Res Clin Endocrinol Metab 2015;29:275-311. DOI PubMed
14. Platt FM, Jeyakumar M. Substrate reduction therapy. Acta Paediatr 2008;97:88-93. DOI PubMed
15. Medin JA, Tudor M, Simovitch R, et al. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase
A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci USA 1996;93:7917-22. DOI
PubMed PMC
16. Takenaka T, Qin G, Brady RO, Medin JA. Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance
for corrective gene transfer for Fabry disease. Hum Gene Ther 1999;10:1931-9. DOI PubMed